

## Antidepressant effects of ER $\beta$ -selective estrogen receptor modulators in the forced swim test

Alicia A. Walf<sup>a</sup>, Madeline E. Rhodes<sup>a</sup>, Cheryl A. Frye<sup>a,b,c,\*</sup>

<sup>a</sup>Department of Psychology, The University at Albany-SUNY, Social Science 220, Albany, NY 12222, USA

<sup>b</sup>Department of Biological Sciences, The University at Albany-SUNY, Albany, NY 12222, USA

<sup>c</sup>The Center for Neuroscience Research, The University at Albany-SUNY, Albany, NY 12222, USA

Received 2 February 2004; received in revised form 17 March 2004; accepted 29 March 2004

### Abstract

Estradiol (E<sub>2</sub>) may influence depressive symptomatology of women and decrease depressive behavior among rodents. The mechanism(s) for E<sub>2</sub>'s antidepressant effects are not well understood. To determine whether antidepressant effects of E<sub>2</sub> may involve actions at intracellular estrogen receptor (ER)  $\alpha$  or  $\beta$  isoforms, selective ER modulators (SERMs) were administered (10  $\mu$ g sc) to ovariectomized rats 48 h before testing in the forced swim test, an animal model of depression, and the horizontal crossing task. Rats received sesame oil vehicle, 17 $\beta$ -E<sub>2</sub>, which has a high affinity for ER $\alpha$  and ER $\beta$ , SERMs that vary in their activity at ER $\alpha$  and  $\beta$ , or a tricyclic antidepressant (desipramine; 30 mg/kg ip), as a positive control. ER $\alpha$ -selective SERMs were propyl pyrazole triol (PPT) and 17 $\alpha$ -E<sub>2</sub>. PPT has more selective effects at ER $\alpha$  than does 17 $\alpha$ -E<sub>2</sub>, which also binds ER $\beta$ . ER $\beta$ -selective SERMs were diarylpropionitrile (DPN) and 7,12-dihydrocoumestan (coumestrol). DPN is more selective at ER $\beta$  than coumestrol, which also binds ER $\alpha$ . 17 $\beta$ -E<sub>2</sub>, ER $\beta$ -selective SERMs (DPN, coumestrol), and desipramine administration produced antidepressive behavior (decreased immobility, increased struggling and swimming). ER $\alpha$ -selective SERMs (PPT, 17 $\alpha$ -E<sub>2</sub>) were not different from vehicle. There were no differences among groups in the number of beam breaks made in the horizontal crossing task. These data suggest that E<sub>2</sub>'s antidepressive effects may involve actions at ER $\beta$ .

© 2004 Elsevier Inc. All rights reserved.

**Keywords:** Estradiol; Estrogen receptor; ER $\alpha$ ; Affect; Sex differences

### 1. Introduction

The ovarian hormone, 17 $\beta$ -estradiol (E<sub>2</sub>), may influence incidence of, or negative symptomatology associated with, depression. Women, compared to men, are twice as likely to experience depression and have longer and more recurrent depressive episodes (Earls, 1987; Nolen-Hoeksema and Ahrens, 2002). Gender differences in depression emerge at puberty (Kessler and Walters, 1998; Lewinsohn et al., 1998; Weissman and Olfson, 1995). Perimenopausal women with depression that receive E<sub>2</sub> replacement have improved mood (Cohen et al., 2003; Schmidt et al., 2000; Soares et al., 2001). In addition, depression scores of postmenopausal women who are not depressed and are taking E<sub>2</sub>-replacement therapy are lower than age-matched women that are

not on E<sub>2</sub> (Miller et al., 2002). Although these data suggest that E<sub>2</sub> may influence depression, E<sub>2</sub>'s effects on, and mechanisms for, depression are not well understood.

Among rodents, there is evidence for antidepressive effects of E<sub>2</sub>. Proestrous rats, which typically have higher E<sub>2</sub>, progesterin, and androgen levels than do diestrous or male rats, demonstrate decreased depressive behavior in the forced swim test (less immobility; Frye and Walf, 2002; Frye and Wawrzycki, 2003). Removal of the primary source of E<sub>2</sub>, progesterins, and androgens [ovariectomy (ovx)] increases depressive behavior of female rats and mice and E<sub>2</sub> replacement reverses this effect (Bernardi et al., 1989; Estrada-Camarena et al., 2003; Frye and Wawrzycki, 2003; Hilakivi-Clarke, 1996; Okada et al., 1997; Rachman et al., 1998; Walf and Frye, submitted for publication). Thus, endogenous increases in, and exogenous replacement of, E<sub>2</sub> may mediate antidepressive behavior of female rodents.

How E<sub>2</sub> has its antidepressant actions is an important question. E<sub>2</sub> may mediate depressive behavior via ligand-dependent actions at intracellular estrogen receptors (ERs).

\* Corresponding author. Department of Psychology, The University at Albany-SUNY, Social Science 220, Albany, NY 12222, USA. Tel.: +1-518-442-4836; fax: +1-518-442-4247.

E-mail address: [cafraye@cnsunix.albany.edu](mailto:cafraye@cnsunix.albany.edu) (C.A. Frye).

E<sub>2</sub>'s effects at ERs involve diffusion of an E<sub>2</sub> and sex hormone binding protein complex through the plasma membrane from the bloodstream. This complex binds to intracellular ERs, causing a conformational change. There is a dissociation of heat shock proteins, and a dimerized pair of E<sub>2</sub>/ER then binds to the E<sub>2</sub> response element (ERE). Following this binding to the ERE and interaction with transcription factors, there is transcription of genes regulated by ERE that carry out cell's functional response (Etgen, 1984; Falkenstein et al., 2000; O'Malley and Means, 1974).

However, traditional actions at a single, ligand-activated transcription factor, ER, may not explain E<sub>2</sub>'s antidepressant effects. In 1996, a second form of ER, ER $\beta$ , was discovered (Kuiper et al., 1996; Tremblay et al., 1997). ER $\alpha$  and ER $\beta$  have distinct N-terminal regions, but share approximately 97% DNA- and approximately 60% ligand-binding domains (Tremblay et al., 1997). ER $\alpha$  and ER $\beta$  are encoded by different genes (Green et al., 1986; Kuiper et al., 1996), show distinct patterns of gene regulation, (Kuiper et al., 1997; Paech et al., 1997; Mitchner et al., 1998; Tena-Sempere et al., 2004), and different patterns of expression in the body and brain at different points in development (Shugrue et al., 1997). Notably, binding affinity, and ligands for, ER $\alpha$  and ER $\beta$  differ (Kuiper et al., 1997), which has led to the development of selective ER modulators (SERMs).

E<sub>2</sub> binds with a high affinity to ER $\alpha$  and ER $\beta$  (Kuiper et al., 1997); thus, actions at either ER $\alpha$  and/or ER $\beta$  may mediate its antidepressant effects. To begin to dissociate the extent to which actions at ER $\alpha$  and/or ER $\beta$  may underlie E<sub>2</sub>'s antidepressant effects, actions of E<sub>2</sub> and various SERMs and a positive control, a tricyclic antidepressant (desipramine), were compared for their effects on depressive behavior in the forced swim task and motor behavior in the horizontal crossing task. If actions at ER $\alpha$  or ER $\beta$  mitigate antidepressant effects, then SERMs selective for ER $\alpha$  or ER $\beta$  should influence behavior in the forced swim test, an animal model of depression.

## 2. Method

These methods were preapproved by the Institutional Animal Care and Use Committee at SUNY Albany.

### 2.1. Animals and housing

Female Long–Evans rats ( $N=224$ ), approximately 55 days old, were either obtained from the breeding colony at SUNY-Albany (original stock from Taconic Farms, Germantown, NY) or were purchased from Taconic Farms. Rats were group housed (four to five per cage) in polycarbonate cages (45 × 24 × 21 cm) in a temperature-controlled room (21 ± 1 °C) in the Laboratory Animal Care Facility. The rats were maintained on a 12:12-h reversed light cycle (lights off 8:00 a.m.) with continuous access to Purina Rat Chow and tap water.

### 2.2. Surgery

All rats were ovariectomized (ovx) under Rompun (12 mg/kg; Bayer, Shawnee Mission, KS) and Ketaset (80 mg/kg; Fort Dodge Animal Health, Fort Dodge, IA) anesthesia 1 week prior to testing.

### 2.3. SERMs and desipramine

Rats were administered sesame oil vehicle, 17 $\beta$ -E<sub>2</sub> (Steroids, Newport, RI), which has equal affinity for ER $\alpha$  and ER $\beta$  (Kuiper et al., 1997), or one of the following SERMs.

ER $\alpha$ -specific SERMs: propyl pyrazole triol (PPT; Tocris Cookson, Ellisville, MO) is a potent selective ER agonist that has 410-fold selectivity for ER $\alpha$  over ER $\beta$  (Stauffer et al., 2000). 17 $\alpha$ -E<sub>2</sub> (Sigma Chemical, St. Louis, MO) is five times more active at ER $\alpha$  than ER $\beta$  (Kuiper et al., 1997).

ER $\beta$ -specific SERMs: diarylpropionitrile (DPN; Tocris Cookson) is a highly selective ER $\beta$  agonist, with 70 times greater activity at ER $\beta$  than ER $\alpha$  (Meyers et al., 2001). 7,12-dihydrocoumestan (coumestrol; Sigma) is a less selective ER $\beta$  agonist, with a sevenfold greater affinity for ER $\beta$  compared to ER $\alpha$  (Kuiper et al., 1997).

As a positive control, some rats were administered a single injection of desipramine hydrochloride, a tricyclic antidepressant (Sigma). Desipramine was freshly made on each day. Desipramine was dissolved in saline to a concentration of 30 mg/ml and was administered to rats via intraperitoneal injection.

### 2.4. Procedure

Ovx rats were randomly assigned to receive vehicle or 10  $\mu$ g 17 $\beta$ -E<sub>2</sub>, PPT, 17 $\alpha$ -E<sub>2</sub>, DPN, or coumestrol 48 h before behavioral testing in either the forced swim test or horizontal crossing task. This dosage and regimen for SERMs was chosen because 10  $\mu$ g E<sub>2</sub> produces physiological levels of E<sub>2</sub> (Vongher and Frye, 1999) and activation of sex behavior, 24–48 h after administration (Frye et al., 1998). Another group of ovx rats was assigned to receive an antidepressant drug regimen consisting of a single intraperitoneal injection of 30 mg/kg desipramine, as has been previously described (Kitamura et al., 2002). Effects of desipramine on depressive and motor behavior after acute administration (30 min before testing) and a regimen analogous to those used with SERMs regimen (48 h before testing) was assessed. This group of desipramine-administered rats served as a positive control in this experiment to validate the forced swim test procedure that was utilized as an animal model of depression.

### 2.5. Behavioral testing

Most rats were tested on two occasions approximately 1–3 weeks apart. Of this group, the majority of rats were first tested in the forced swim test and then in the horizontal crossing task on a second occasion; however, some rats in

each group were tested in the opposite order and there was no observed effect of testing order. Some rats were only tested in the forced swim test or the horizontal crossing task; there was no evidence of differences in these rats' performance compared to rats that were tested in both tasks. Forced swim test behavior was observed, and manually recorded, by one trained investigator (AAW). The number of beam breaks mechanically recorded in the horizontal crossing task was documented by one of four trained observers. All were blind to the hypothesized outcome of the experiments.

### 2.5.1. Forced swim task

A modified version of the forced swim test, behavior which is sensitive to antidepressant treatment, was utilized (Frye and Walf, 2002; Overstreet et al., 1995; Porsolt et al., 1977; Zangen et al., 1997). The duration rats spent struggling, swimming, and immobile in a cylindrical container filled with 30 cm of 30 °C water was recorded for 10 min. This temperature of water was utilized because it has been used by our laboratory and others in the past to assess steroids' or neurotransmitters' effects on depressive behavior (Chau et al., 2001; Frye and Walf, 2002; Frye and Wawrzycki, 2003; Rada et al., 2003) and lower temperature water, such as 25 °C water, reduces body and brain temperature and/or produces hypothermia simultaneously with the expression of immobility behavior of rodents (Abel, 1993; Arai et al., 2000; Taltavull et al., 2003). Struggling is defined as the movement of the forelimbs in rapid fashion that break the surface of the water, climbing, and/or clinging to the walls of the chamber. Swimming is defined as movement of the forelimbs and/or hindlimbs that do not break the surface of the water and/or the movement

of rats while they are underwater. Immobility, an index of depressive behavior, consisted of the lack of any movements typical of struggling or swimming and only the slight, if any, movements necessary for the rat to keep its head above water (i.e., floating).

### 2.5.2. Horizontal crossing task

To assess effects of SERMs and desipramine on motor behavior of rats, the horizontal crossing task was used as per Frye et al. (2000). Rats were placed in a 39 × 39 × 30 cm Digiscan Optical Animal Activity Monitor (Accuscan Instruments, Columbus, OH) that mechanically recorded the number of beam breaks that occurred during a 5-min period.

### 2.6. Statistical analyses

One-way analyses of variance (ANOVAs) were utilized to determine if there were differences among SERMs' effects on behavior in the forced swim or horizontal crossing test. The  $\alpha$  level for statistical significance was  $P < .05$ . Where appropriate, Fisher's post hoc tests were used to determine group differences.

## 3. Results

### 3.1. Forced swim test (see Fig. 1 and Table 1)

17 $\beta$ -E<sub>2</sub>, ER $\beta$ -selective SERMs, and desipramine (when administered both 30-min and 48-h before testing) regimen had antidepressant effects in the forced swim test compared to vehicle (Fig. 1 and Table 1). There were differences among groups in the time spent immobile




Fig. 1. The mean ( $\pm$  S.E.M.) duration spent immobile in the forced swim test of ovx rats administered vehicle, 17 $\beta$ -E<sub>2</sub>, PPT, 17 $\alpha$ -E<sub>2</sub>, DPN, coumestrol (COUM), or desipramine 30 min or 48 h before testing. \* Indicates a significant difference from vehicle, PPT, and 17 $\alpha$ -E<sub>2</sub> ( $P < .05$ ).

Table 1  
Duration of struggling and swimming ( $\pm$  S.E.M.) in the forced swim test ( $n = 14$ )

|                                    | Duration of struggling | Duration of swimming |
|------------------------------------|------------------------|----------------------|
| <i>SERM (10 <math>\mu</math>g)</i> |                        |                      |
| Vehicle                            | 106.4 $\pm$ 7.1        | 143.0 $\pm$ 11.9     |
| 17 $\beta$ -E <sub>2</sub>         | 167.9 $\pm$ 16.2 *     | 250.4 $\pm$ 14.5 *   |
| PPT                                | 134.6 $\pm$ 8.5        | 121.3 $\pm$ 6.0      |
| 17 $\alpha$ -E <sub>2</sub>        | 153.6 $\pm$ 12.2       | 131.4 $\pm$ 14.0     |
| DPN                                | 177.9 $\pm$ 9.2 *      | 252.4 $\pm$ 13.7 *   |
| Coumestrol                         | 178.7 $\pm$ 10.4 *     | 220.7 $\pm$ 9.1 *    |
| <i>Desipramine (30 mg/kg)</i>      |                        |                      |
| 30 min                             | 215.1 $\pm$ 14.6 *     | 200.0 $\pm$ 13.6 *   |
| 48 h                               | 222.9 $\pm$ 12.0 *     | 186.1 $\pm$ 11.1 *   |

\* Indicates a significant difference from vehicle, PPT, and 17 $\alpha$ -E<sub>2</sub> ( $P < .05$ ).

[ $F(7,104) = 51.635$ ,  $P < .0001$ ], struggling [ $F(7,104) = 11.519$ ,  $P < .00014$ ], and swimming [ $F(7,104) = 18.662$ ,  $P < .0001$ ]. Post hoc tests revealed that 17 $\beta$ -E<sub>2</sub>, DPN, or coumestrol (which all bind ER $\beta$ ) reduced duration of time spent immobile and increased the duration of time spent struggling or swimming compared to rats administered vehicle, PPT, or 17 $\alpha$ -E<sub>2</sub>. Administration of desipramine 30 min or 48 h before testing similarly reduced time spent immobile and increased time spent struggling and swimming compared to vehicle, PPT, and 17 $\alpha$ -E<sub>2</sub>.

### 3.2. Horizontal crossing task (see Fig. 2)

There were no significant differences in the number of beam breaks of rats administered vehicle, 17 $\beta$ -E<sub>2</sub>, ER $\beta$ -selective SERMs, ER $\alpha$ -selective SERMs, or desipramine 30 min or 48 h prior to testing ( $P > .6373$ ) (Fig. 2).

## 4. Discussion

Results of the present experiment support the hypothesis that E<sub>2</sub>'s effects for antidepressant behavior involve selective actions at ER $\beta$ . Rats administered 17 $\beta$ -E<sub>2</sub>, DPN, or coumestrol, all with actions at ER $\beta$ , exhibited similar antidepressive behavior as rats administered the tricyclic antidepressant, desipramine, and less depressive behavior than did rats administered ER $\alpha$ -selective SERMs (PPT or 17 $\alpha$ -E<sub>2</sub>) or vehicle. Administration of vehicle, SERMs, or desipramine did not significantly alter motor behavior in the horizontal crossing task. Together, these data suggest that E<sub>2</sub>'s effects to mediate antidepressive behavior in the forced swim test may involve actions at ER $\beta$ .

The effects of E<sub>2</sub>, compared to vehicle, to decrease immobility in the forced swim test are consistent with previous reports of E<sub>2</sub>'s antidepressant effects. Proestrous rats, which have higher endogenous E<sub>2</sub> levels, demonstrate less depressive behavior in the forced swim test than do diestrous or male rats, with relatively lower E<sub>2</sub> levels (Frye and Walf, 2002; Frye and Wawrzycki, 2003). OvX increases depressive behavior of female rodents in the tail suspension and forced swim test and E<sub>2</sub> administration attenuates these effects (Bernardi et al., 1989; Estrada-Camarena et al., 2003; Frye and Wawrzycki, 2003; Hilakivi-Clarke, 1996; Okada et al., 1997; Rachman et al., 1998; Walf and Frye, submitted for publication). These previous reports of E<sub>2</sub>'s ability to reduce depressive behavior in the forced swim test have used various E<sub>2</sub> regimen, including 5 or 10  $\mu$ g E<sub>2</sub> subcutaneous injections for 48 h (Estrada-Camarena et al., 2003; Walf and Frye, submitted for publication), 5  $\mu$ g E<sub>2</sub> injections for 22 and 44 h (Frye and Wawrzycki, 2003), 10  $\mu$ g E<sub>2</sub> subcutaneous injections daily for 7 days (Rachman et al.,




Fig. 2. The mean ( $\pm$  S.E.M.) number of beam breaks made in the horizontal crossing task of ovx rats administered vehicle, 17 $\beta$ -E<sub>2</sub>, PPT, 17 $\alpha$ -E<sub>2</sub>, DPN, coumestrol (COUM), or desipramine 30 min or 48 h before testing.



1998), and subcutaneous E<sub>2</sub> pellets for 60 days (Hilakivi-Clarke, 1996) before testing. Although these reports demonstrate that various E<sub>2</sub> regimen produce antidepressive effects in the forced swim test, not all studies have reported this, suggesting that E<sub>2</sub>'s effects to reduce depressive behavior in this task may depend upon regimen utilized. For instance, administration of lower (Estrada-Camarena et al., 2003; Walf and Frye, submitted for publication) and higher dosages of E<sub>2</sub> does not reduce immobility of ovx rats (Stoffel and Craft, 2003; Walf and Frye, submitted for publication). It may be that regimen that produce physiological levels of E<sub>2</sub> may be necessary to produce antidepressant effects.

Effectiveness of E<sub>2</sub> or antidepressant treatment to reduce depressive behavior may be due in part to duration of treatment. There is evidence for antidepressive effects of E<sub>2</sub> with acute administration (22–48 h before testing; Estrada-Camarena et al., 2003; Frye and Wawrzycki, 2003; Walf and Frye, submitted for publication). However, some studies have found that chronic administration of E<sub>2</sub>, which likely produces prolonged supraphysiological or physiological plasma E<sub>2</sub> levels, does not decrease depressive behavior in the forced swim test of ovx rodents (Galea et al., 2002; Okada et al., 1997), but this effect has not been observed in all studies (Hilakivi-Clarke, 1996). Alternatively, antidepressant treatments are typically chronic. Among people, reductions in depressive symptomology are typically delayed 4–6 weeks after chronic antidepressant treatment is initiated (Montgomery, 1999). Antidepressants are typically administered chronically in animal studies as well. However, the present results extend previous findings of reduced depressive behavior in the forced swim test following a single, acute (30 mg/kg, 30 min before testing; Kitamura et al., 2002) desipramine regimen in rats.

Investigators have been trying to find novel compounds that produce antidepressant effects more rapidly than classical antidepressants. Thus, the present findings, that single, acute treatments with 17 $\beta$ -E<sub>2</sub> or SERMs with actions at ER $\beta$  produce similar effects as are observed with desipramine administration reduce depressive behavior, may have great clinical significance. For instance, it may be possible that these SERMs could be used as adjunctive therapy in the weeks prior to the onset of antidepressant action, when an acute treatment is imperative. In addition to a shorter onset of action, another benefit of the use of SERMs may be that they could minimize the sexual side effects associated with some antidepressant therapies (Lane, 1997). As well, studies examining distribution of ER $\alpha$  and ER $\beta$  indicate that the uterus and breast epithelium lack ER $\beta$  (see Gustafsson, 2003 for review). Given that a significant concern about hormone-replacement therapy is the negative, proliferative effects of E<sub>2</sub> on these tissues, it is possible that ER $\beta$ -selective SERMs may reduce these side-effects.

That ER $\beta$ -selective SERMs had antidepressant effects similar to E<sub>2</sub> extends previous findings regarding tamoxifen's and ER $\beta$ -active SERMs' effects on mood. Tamoxifen,

a compound with antiestrogenic effects in the nanomolar range, is commonly used to treat women with breast cancer. Tamoxifen has been reported to increase the prevalence of depression in some (Breuer and Anderson, 2000; Shariff et al., 1995), but not all studies (Nystedt et al., 2003; Day et al., 2001). To date, there are no studies of tamoxifen on affective behavior of rodents that we are aware of, but it has been shown to increase stress responses of female rats (Young et al., 2001). Second, although we are unaware of any other reports of SERMs' effects on depressive behavior in rodents, ER $\beta$ -selective SERMs may alter anxiety behavior in the elevated plus maze. Male and female rats fed a diet rich in phytoestrogens, with ER $\beta$  selectivity, made more entries onto, and spent more time on the open arms of the elevated plus maze than did rats fed a phytoestrogen-free diet (Lund and Lephart, 2001). These data, together with our present results, suggest that E<sub>2</sub>'s ability to modulate affective processes may involve actions at ER $\beta$ .

Although E<sub>2</sub>, SERMs with activity at ER $\beta$ , and desipramine reduced immobility, these effects were not independent of changes in struggling and swimming, compared to rats administered vehicle or SERMs with activity at ER $\alpha$ . E<sub>2</sub>'s ability to increase running-wheel and open-field activity of rodents is well known (Morgan and Pfaff, 2001, 2002). However, our present results using the horizontal crossing task do not reveal robust differences between groups on motor behavior in this task. Thus, these results suggest that all differences in the forced swim test between groups observed may not be entirely due to differences in motor behavior.

Although data from the present study are exciting, as they suggest a potentially beneficial effect of actions at ER $\beta$  on depressive behavior, they are not without limitations. First, effects of only a single 10- $\mu$ g dosage of each SERM was investigated. This regimen was utilized because 10  $\mu$ g E<sub>2</sub> is sufficient to produce physiological E<sub>2</sub> concentrations and facilitate sex behavior (Frye et al., 1998; Vongher and Frye, 1999). Given that some SERMs have greater activity at ER $\alpha$  or ER $\beta$ , than E<sub>2</sub>, one concern might be that a 10- $\mu$ g dosage produces high enough concentrations such that selectivity for ERs is obviated. However, the pattern of the SERMs' antidepressant effects followed their reported activity at ER $\beta$ . Rats administered DPN, which is the most selective for ER $\beta$ , have the shortest duration of immobility, followed by rats administered 17 $\beta$ -E<sub>2</sub> < coumestrol < 17 $\alpha$ -E<sub>2</sub> < PPT < vehicle. Second, in the present study, we used only one highly selective and one less-selective SERM. The data suggest that a high level of activity at ER $\beta$  is not necessary, as coumestrol, which is only seven times more active at ER $\beta$  than ER $\alpha$ , was effective at decreasing depressive behavior. Investigating effects of other SERMs with different levels of activity at ER $\beta$  (and/or ER $\alpha$ ) may reveal the threshold amount of activity at these substrates that is necessary for behavioral effects. Third, although the present results do not support a role of ER $\alpha$ , we cannot rule out its involvement in these processes. Indeed, evidence

suggests that ER $\beta$  may have a modulatory role on ER $\alpha$  by inhibiting ER $\alpha$ -mediated gene transcription and/or partially replacing ER $\alpha$  in its absence (Lindberg et al., 2003). Finally, our interpretation of the present data is based upon the selectivity of the SERMs at ER $\alpha$  and ER $\beta$ . However, it is possible that the ability of the SERMs to affect other receptors, processes, and/or systems may mediate some of their effects on antidepressant behavior (Kian Tee et al., 2004). For these reasons, it is necessary to expand the current investigation to more dosages of these and other SERMs to determine how they may modulate affective processes and activity at ER $\alpha$  and ER $\beta$ .

In summary, these data suggest that E<sub>2</sub>'s antidepressive effects may be due in part to actions at ER $\beta$ . Further investigation is needed to increase our understanding of E<sub>2</sub>'s role and mechanisms for affect. Such information is critical so that women may make more informed choices about existing therapies and to enable the development of more selective therapies with fewer side effects.

## Acknowledgements

This research was supported by grants from the National Science Foundation (IBN 98-96263; DBI 00-97343; IBN 03-16083). The technical assistance provided by Sheena Ballard, Chih Chin, Bushra Helmandi, and Jennifer Marrone is greatly appreciated.

## References

- Abel EL. Physiological correlates of the forced swim test in rats. *Physiol Behav* 1993;54:309–17.
- Arai I, Tsuyuki Y, Shiimoto H, Satoh M, Otomo S. Decreased body temperature dependent appearance of behavioral despair in the forced swimming test in mice. *Pharmacol Res* 2000;42:171–6.
- Bernardi M, Vergoni AV, Sandrini M, Tagliovini SB. Influence of ovariectomy, estradiol and progesterone on the behavior of mice in an experimental model of depression. *Physiol Behav* 1989;45:1067–8.
- Breuer B, Anderson R. The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents. *Women Health* 2000;31:71–85.
- Chau DT, Rada P, Kosloff RA, Taylor JL, Hoebel BG. Nucleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant-like effects of local M1 antagonist in the Porsolt swim test. *Neuroscience* 2001;104:791–8.
- Cohen LS, Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. *Am J Psychiatry* 2003;160:1519–22.
- Day R, Ganz PA, Costantino JP. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. *J Natl Cancer Inst* 2001;93:1615–23.
- Earls F. Sex differences in psychiatric disorders: origins and developmental influences. *Psychiatr Dev* 1987;5:1–23.
- Estrada-Camarena E, Fernandez-Guasti A, Lopez-Rubalcava C. Antidepressant-like effect of different estrogenic compounds in the forced swimming test. *Neuropsychopharmacology* 2003;28:830–8.
- Etgen AM. Progestin receptors and the activation of female reproductive behavior: a critical review. *Horm Behav* 1984;18:411–30.
- Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M. Multiple actions of steroid hormones—a focus on rapid, nongenomic effects. *Pharmacol Rev* 2000;52:513–56.
- Frye CA, Walf AA. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of pre-ovulatory rats. *Horm Behav* 2002;41:306–15.
- Frye CA, Wawrzycki J. Effect of prenatal stress and gonadal hormone condition on depressive behaviors of female and male rats. *Horm Behav* 2003;44:319–26.
- Frye CA, Bayon LE, Pursnani NK, Purdy RH. The neurosteroids, progesterone and 3 $\alpha$ ,5 $\alpha$ -THP, enhance sexual motivation, receptivity, and proceptivity in female rats. *Brain Res* 1998;808:72–83.
- Frye CA, Petralia SM, Rhodes ME. Estrous cycle and sex differences in performance on anxiety tasks coincide with increases in hippocampal progesterone and 3 $\alpha$ , 5 $\alpha$ -THP. *Pharmacol Biochem Behav* 2000;67:587–96.
- Galea LA, Lee TT, Kostaras X, Sidhu JA, Barr AM. High levels of estradiol impair spatial performance in the Morris water maze and increase 'depressive-like' behaviors in the female meadow vole. *Physiol Behav* 2002;77:217–25.
- Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erbA. *Nature* 1986;320:134–1349.
- Gustafsson JA. What pharmacologists can learn from recent advances in estrogen signalling. *Trends Pharmacol Sci* 2003;24:479–85.
- Hilakivi-Clarke L. Role of estradiol in alcohol intake and alcohol-related behaviors. *J Stud Alcohol* 1996;57:162–70.
- Kessler RC, Walters EE. Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey. *Depress Anxiety* 1998;7:3–14.
- Kian Tee M, Rogatsky I, Tzagarakis-Foster C, Cvaro A, An J, Christy RJ, et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors { $\alpha$ } and { $\beta$ }. *Mol Biol Cell* 2004;15:1262–72.
- Kitamura Y, Araki H, Gomita Y. Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test. *Pharmacol Biochem Behav* 2002;71:63–9.
- Kuiper GG, Enmark E, Peltö-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. *Proc Natl Acad Sci* 1996;93:5925–30.
- Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors  $\alpha$  and  $\beta$ . *Endocrinology* 1997;138:863–70.
- Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. *J Psychopharmacol* 1997;11:72–82.
- Lewinsohn PM, Rohde P, Seeley JR. Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. *Clin Psychol Rev* 1998;18:765–94.
- Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson JA, et al. Estrogen receptor (ER)- $\beta$  reduces ER $\alpha$ -regulated gene transcription, supporting a "ying yang" relationship between ER $\alpha$  and ER $\beta$  in mice. *Mol Endocrinol* 2003;17:203–8.
- Lund TD, Lephart ED. Dietary soy phytoestrogens produce anxiolytic effects in the elevated plus-maze. *Brain Res* 2001;913:180–4.
- Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor- $\beta$  potency-selective ligands: structure–activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. *J Med Chem* 2001;44:4230–51.
- Miller KJ, Conney JC, Rasgon NL, Fairbanks LA, Small GW. Mood symptoms and cognitive performance in women estrogen users and nonusers and men. *J Am Geriatr Soc* 2002;50:1826–30.
- Mitchner NA, Garlick C, Ben-Jonathan N. Cellular distribution and gene

- regulation of estrogen receptors  $\alpha$  and  $\beta$  in the rat pituitary gland. *Endocrinology* 1998;139:3976–83.
- Montgomery SA. New developments in the treatment of depression. *J Clin Psychiatry* 1999;60:10–5.
- Morgan MA, Pfaff DW. Effects of estrogen on activity and fear-related behaviors in mice. *Horm Behav* 2001;40:472–82.
- Morgan MA, Pfaff DW. Estrogen's effects on activity, anxiety, and fear in two mouse strains. *Behav Brain Res* 2002;132:85–93.
- Nolen-Hoeksema S, Ahrens C. Age differences and similarities in the correlates of depressive symptoms. *Psychol Aging* 2002;17:116–24.
- Nystedt M, Berglund G, Bolund C, Fornander T, Rutqvist LE. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. *J Clin Oncol* 2003;21:1836–44.
- Okada M, Hayashi N, Kometani M, Nakao K, Inukai T. Influences of ovariectomy and continuous replacement of 17 $\beta$ -estradiol on the tail skin temperature and behavior in the forced swimming test in rats. *Jpn J Pharmacol* 1997;73:93–6.
- O'Malley BW, Means AR. Female steroid hormones and target cell nuclei. *Science* 1974;183:610–20.
- Overstreet DH, Pucilowski O, Rezvani AH, Janowsky DS. Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. *Psychopharmacology* 1995;121:27–37.
- Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, et al. Differential ligand activation of estrogen receptors ER $\alpha$  and ER $\beta$  at AP1 sites. *Science* 1997;277:1508–10.
- Porsolt R, LePichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. *Nature* 1977;266:730–2.
- Rachman IM, Unnerstall JR, Pfaff DW, Cohen RS. Estrogen alters behavior and forebrain *c-fos* expression in ovariectomized rats subjected to the forced swim test. *Proc Natl Acad Sci* 1998;95:13941–6.
- Rada P, Moreno SA, Tucci S, Gonzalez LE, Harrison T, Chau DT, et al. Glutamate release in the nucleus accumbens is involved in behavioral depression during the PORSOLT swim test. *Neuroscience* 2003;119:557–65.
- Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. *Am J Obstet Gynecol* 2000;183:414–20.
- Shariff S, Cumming CE, Lees A, Handman M, Cumming DC. Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist. An expected or unexpected effect? *Ann N.Y. Acad Sci* 1995;761:365–8.
- Shugrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor- $\alpha$  and - $\beta$  mRNA in the rat central nervous system. *J Comp Neurol* 1997;388:507–25.
- Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. *Arch Gen Psychiatry* 2001;58:529–34.
- Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, et al. Pyrazole ligands: structure–affinity/activity relationships and estrogen receptor- $\alpha$ -selective agonists. *J Med Chem* 2000;43:4934–47.
- Stoffel E.C., Craft R.M.. The effects of postpartum hormone withdrawal on depression and anxiety indices in female rats. *Abstr.-Soc Neurosci* 2003 p. 27.
- Taltavull JF, Chefer VI, Shippenberg TS, Kiyatkin EA. Severe brain hypothermia as a factor underlying behavioral immobility during cold-water forced swim. *Brain Res* 2003;975:244–7.
- Tena-Sempere M, Navarro VM, Mayen A, Bellido C, Sanchez-Criado JE. Regulation of estrogen receptor (ER) isoform messenger RNA expression by different ER ligands in female rat pituitary. *Biol Reprod* 2004;70:671–8.
- Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor  $\beta$ . *Mol Endocrinol* 1997;11:353–65.
- Vongher JM, Frye CA. Progesterone in conjunction with estradiol has neuroprotective effects in an animal model of neurodegeneration. *Pharmacol Biochem Behav* 1999;64:777–85.
- Walf AA, Frye CA. Restraint stress attenuates anti-anxiety and anti-depressive behavior produced by physiological estradiol regimen. *Neuropsychopharmacology* [submitted for publication].
- Weissman MM, Olfson M. Depression in women: implications for health care research. *Science* 1995;269:799–801.
- Young EA, Altemus M, Parkison V, Shastry S. Effects of estrogen antagonists and agonists on the ACTH response to restraint stress in female rats. *Neuropsychopharmacology* 2001;25:881–91.
- Zangen A, Overstreet DH, Yadid G. High serotonin and 5-hydroxyindoleacetic acid levels in limbic brain regions in a rat model of depression: normalization by chronic antidepressant treatment. *J Neurochem* 1997;69:2477–83.